InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,018.39
(
-0.34%
)
US TECH 100
16,954.40
(
-0.17%
)
Dow Jones
37,903.29
(
0.23%
)
Brent Oil
83.89
(
0.42%
)
Bitcoin
57,451.07
(
-1.35%
)
Post# of 38376
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

JokersWild12

Send PM Follow Ignore
Followers 10
Posts 529
Boards Moderated 0
Alias Born 12/15/2011

JokersWild12

Re: ronrooster post# 38137

Sunday, 06/18/2017 1:03:57 PM

Sunday, June 18, 2017 1:03:57 PM

Post# of 38376
If ENTB does develop drug cures for inflammatory animal diseases and canine cancer the valuation will be well over $1. Keep in mind that one of Entest's competitors is Aratana Therapeutics(PETX) which has a similar share structure(38M), and has a current share price of $6.43, market cap of $239M. Still a development company. Which allow shows how undervalued ENTB is right now. So if Entest scores on drugs for inflammation(arthritis, other), and cancer this company will have significant value to a big BP.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up